SKYEY - SkyePharma PLC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SKYEY - SkyePharma PLC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Trippi who wrote (2)	3/22/1999 8:23:00 AM
From: Dr. John M. de Castro	Read Replies (1) of 56

The rights, to the best of my knowledge are for the additional SKYEY shares that are due if milestones are hit. This is from the Edgar filing: >> "Additional contingent payments would be made by SkyePharma if certain milestones are met by DepoTech. These would be triggered as follows: o An additional 1.06 ADS for each 10 shares of DepoTech Common Stock if DepoCyt is launched in the U.S. no later than March 31st, 2000, and o An additional 0.79 ADS for each 10 shares of DepoTech Common Stock if either of the following events occur before March 31st, 2000: o A development agreement is signed with a corporate partner for DepoMorphine, or o A development agreement is signed with a corporate partner for a macromolecule using DepoTech's DepoFoam technology. ">> Let us know if your hear differently. Yes I did hold through the merger. I wanted these rights. There is a high probability that DepoCyt will be approved. In which case I will have .106 SKYEY extra for each DEPO share. The second contingency is IMHO a wild card. But, it's worth holding for the just in case. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next